Michelle Hundt
Family · Southbury, CTNPI 1952452872
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 283 payments — averaging $43.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$882
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$870
- plus $5K from 23 others
What the payments were for
- Food & beverage$12,432100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $2,682 |
| Otsuka America Pharmaceutical, Inc. | 19 | $1,202 |
| Axsome Therapeutics, Inc. | 14 | $1,186 |
| Teva Pharmaceuticals USA, Inc. | 11 | $1,096 |
| Alkermes, Inc. | 26 | $882 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $870 |
| Johnson & Johnson | 15 | $807 |
| Neurocrine Biosciences, Inc. | 6 | $503 |
| Novo Nordisk | 15 | $492 |
| AstraZeneca | 4 | $399 |
| Idorsia Pharmaceuticals US Inc | 6 | $300 |
| Lilly USA, LLC | 5 | $219 |
| Lundbeck LLC | 9 | $215 |
| Merck | 3 | $170 |
| Scilex Pharmaceuticals Inc. | 7 | $170 |
| Braeburn Inc. | 3 | $152 |
| Avanir Pharmaceuticals, Inc. | 2 | $147 |
| Corium, LLC | 7 | $138 |
| Indivior Inc. | 6 | $133 |
| Eisai Inc. | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $118 |
| Pfizer | 4 | $77 |
| GSK | 3 | $61 |
| Almatica Pharma LLC | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Optinose US, Inc. | 1 | $30 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$1,204
- Auvelity$996
- LYBALVI$880
- REXULTI$748
- Austedo XR$491
- ARISTADA$480
- INGREZZA$472
- CAPLYTA$377
- AUSTEDO$250
- VERQUVO$250
- QUVIVIQ$248
- Wegovy$245
- UZEDY$233
- INVEGA SUSTENNA$218
- Dayvigo$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- KISUNLA$125
- BRIXADI$125
- NUEDEXTA$124
How this compares
$12,432 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $24,283 |
| LinzessLinaclotide | 11 | $5,861 |
| Chlorthalidone | 17 | $483 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $264 |
| Levothyroxine Sodium | 15 | $197 |
| Fluticasone Propionate | 17 | $180 |
| Gabapentin | 19 | $179 |
| Amlodipine Besylate | 18 | $169 |
| Losartan Potassium | 23 | $138 |
| Rosuvastatin Calcium | 13 | $117 |
| Escitalopram Oxalate | 13 | $105 |
| Atorvastatin Calcium | 21 | $99 |
| Metformin Hcl | 27 | $88 |
| Alprazolam | 13 | $77 |
| Lisinopril | 17 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $2,682 | $30,14424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Southbury
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Diana BytyqiDerby$53K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.